Description
NCLT approved merger scheme with record date August 14, 2025, and trading suspension for Ind-Swift Limited shares.
Summary
BSE has announced the amalgamation of Ind-Swift Limited (Scrip Code: 524652) into Ind-Swift Laboratories Limited as approved by the NCLT Chandigarh Bench. Trading in Ind-Swift Limited shares will be suspended from August 14, 2025, with shareholders receiving 15 shares of Ind-Swift Laboratories Limited for every 100 shares held.
Key Points
- NCLT Chandigarh Bench has approved the Scheme of Arrangement for amalgamation
- Ind-Swift Limited is the transferor company merging into Ind-Swift Laboratories Limited
- Record date fixed as August 14, 2025
- Share exchange ratio: 15 shares of Ind-Swift Laboratories (Rs. 10 face value) for every 100 shares of Ind-Swift Limited (Rs. 2 face value)
- Trading suspension effective from August 14, 2025
Regulatory Changes
Implementation of NCLT approved Scheme of Arrangement resulting in complete merger of Ind-Swift Limited into Ind-Swift Laboratories Limited.
Compliance Requirements
- Trading members must not deal in Ind-Swift Limited equity shares from August 14, 2025
- Shareholders entitled to receive new shares as per the approved exchange ratio
- All trading activities in the scrip must cease on the specified date
Important Dates
- Record Date: August 14, 2025
- Trading Suspension Date: August 14, 2025
- Notice Date: August 11, 2025
Impact Assessment
High impact corporate action affecting all shareholders of Ind-Swift Limited. Complete trading suspension will prevent any further transactions in the scrip. Shareholders will experience automatic conversion of their holdings at the specified ratio, potentially affecting portfolio composition and liquidity.
Impact Justification
Complete trading suspension and mandatory corporate action affecting all shareholders